Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13754MR)

This product GTTS-WQ13754MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13754MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ67MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ5113MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ689MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ10322MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ7004MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ9099MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ11802MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ1365MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW